GRAL trades 18.6% above Wall Street's consensus target of $107.88.
Last 12 months price action with 12-month analyst target path
The base valuation assumes GRAL achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 24, 2026, GRAIL Inc. (GRAL) has a Wall Street consensus price target of $107.88, based on estimates from 8 covering analysts. With the stock currently trading at $132.55, this represents a potential downside of -18.6%. The company has a market capitalization of $5.69B.
Analyst price targets range from a low of $56.00 to a high of $175.00, representing a 110% spread in expectations. The median target of $109.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, GRAL trades at a trailing P/E of -11.9x. Analysts expect EPS to grow -4.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EXASExact Sciences Corporation | $20.0B | $104.91 | $92.95 | -11.4% | Buy | 582.8x | 41 |
 ILMNIllumina, Inc. | $40.8B | $269.42 | $252.73 | -6.2% | Buy | 50.3x | 50 |
 GHGuardant Health, Inc. | $22.4B | $169.08 | $202.40 | +19.7% | Buy | — | 31 |
 NTRANatera, Inc. | $57.9B | $403.95 | $379.13 | -6.1% | Buy | — | 28 |
 FDMT4D Molecular Therapeutics, Inc. | $565M | $10.80 | $29.67 | +174.7% | Buy | — | 14 |
 ACMRACM Research, Inc. | $3.2B | $50.55 | $113.20 | +123.9% | Buy | 22.8x | 10 |
 CDNACareDx, Inc | $3.6B | $69.21 | $62.25 | -10.1% | Buy | 57.8x | 14 |
 PACBPacific Biosciences of California, Inc. | $655M | $2.11 | $1.93 | -8.5% | Buy | — | 18 |
 SEERSeer, Inc. | $108M | $1.97 | $4.00 | +103.0% | Hold | — | 4 |
 TMOThermo Fisher Scientific Inc. | $250.4B | $673.82 | $688.14 | +2.1% | Buy | 26.7x | 43 |
Quick answers to the most common questions about buying GRAL stock.
GRAL's consensus price target is $107.88, -18.6% below the current price of $132.55. The 8 analysts tracking GRAL see downside risk at present valuations.
GRAL has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $107.88 implies -18.6% downside from current levels.
GRAL's current price is $132.55 with a consensus target of $107.88 (-18.6% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $175 for GRAL, while the most conservative target is $56. The consensus of $107.88 represents the median expectation. These targets typically reflect 12-month expectations.
GRAL is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GRAL stock forecast based on 8 Wall Street analysts shows a consensus price target of $107.88, with estimates ranging from $56 (bear case) to $175 (bull case). The median consensus rating is "Buy".
Analysts are cautious on GRAL, with 0 Sell ratings and a price target of $107.88 (-18.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GRAL analyst price targets range from $56 to $175, a 110% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $107.88 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.